12 May 2026
12 May 2026
The study will enrol around 50 high-risk coronary artery disease patients whose resting ECGs show no signs of ischemia.
The Phase II segment enrolled 68 patients, with 33 assigned to the combination arm and 35 to the pembrolizumab-only arm.
The FDA approval was based on data from the multi-centre, open-label Phase II eNRGy clinical trial.
The leased facility will manufacture diagnostic instruments, equipment, and consumables.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
